missing translation for 'onlineSavingsMsg'
Learn More
  1. Home
  2. Products
  3. Antibodies
  4. Primary Antibodies
  5. All Primary Antibodies
  6. 30287529

Daxx Antibody (CL3580) [DyLight 488], Novus Biologicals™

Mouse Monoclonal Antibody

Brand:  Novus Biologicals NBP2-61622G

Product Code. 30287529

  • 737.00 € / 0.10mL

Please to purchase this item. Need a web account? Register with us today!

This item is not returnable. View return policy

Description

Description

Daxx Monoclonal antibody specifically detects Daxx in Human samples. It is validated for Immunohistochemistry,Immunohistochemistry (Paraffin),Immunocytochemistry/ Immunofluorescence
TRUSTED_SUSTAINABILITY
Specifications

Specifications

Daxx
Monoclonal
DyLight 488
BING2, CENP-C binding protein, DAP6MGC126245, Daxx, death domain-associated protein 6, death-associated protein 6, death-domain associated protein, EAP1, ETS1-associated protein 1, Fas death domain-associated protein, Fas-binding protein, hDaxx, MGC126246
This antibody was developed using a recombinant protein derived from Q9UER7, with the exact immunogen sequence remaining proprietary.
0.1 mL
Apoptosis, Cancer, Phospho Specific, Tumor Suppressors
1616
Store at 4⪚C in the dark.
IgG1
Immunohistochemistry, Immunohistochemistry (Paraffin), Immunocytochemistry/Immunofluorescence
CL3580
50mM Sodium Borate
Mouse
Protein A purified
RUO
Primary
Human
Purified
Product Suggestions

Product Suggestions

Videos
SDS
Documents

Documents

Certificates
Promotions

Promotions

Product Content Correction

Your input is important to us. Please complete this form to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Thank You! Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.